Search
Immunome Inc
IMNMAdd to Watchlist
23.610USD
+2.120+9.87%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
2.67BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+9.87%
5 Days
+18.29%
1 Month
+19.97%
6 Months
+13.40%
Year to Date
+9.92%
1 Year
+167.08%
Key Figures
21.600Open
23.670High
1.87MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.65%Turnover Ratio
21.490Prev. Close
21.260Low
32.56MTurnover
LossP/E Static
4.54P/B
0.00%Div Yield TTM
-46.67%ROA
27.65052wk High
1.39Volume Ratio
-292.96MNet Profit
113.17MShares
-2.3830EPS TTM
2.07Beta
-50.14%ROE
7.96052wk Low
11.21%Amplitude
100.00%Gross Margin
2.67BMarket Cap
2.24Reward/Risk
4.10%Risk Rate
TradingKey Stock Score of Immunome Inc
Currency: USD Updated: 2026-07-02Key Insights
Immunome Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 29 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.50.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Immunome Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Immunome Inc Highlights
StrengthsRisks
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.94M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 6.94M.
Undervalued
The company’s latest PE is -9.91, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 116.25M shares, increasing 11.97% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 35.76K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.36.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
35.500
Target Price
+65.19%
Upside Space
Immunome Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Immunome Inc Info
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Ticker SymbolIMNM
CompanyImmunome Inc
CEOSiegall (Clay B)
Websitehttps://immunome.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Immunome Inc (IMNM)?
The current price of Immunome Inc (IMNM) is 23.61.
What is the symbol of Immunome Inc?
The ticker symbol of Immunome Inc is IMNM.
What is the 52-week high of Immunome Inc?
The 52-week high of Immunome Inc is 27.65.
What is the 52-week low of Immunome Inc?
The 52-week low of Immunome Inc is 7.96.
What is the market capitalization of Immunome Inc?
The market capitalization of Immunome Inc is 2.67B.
Is Immunome Inc (IMNM) currently rated as Buy, Hold, or Sell?
According to analysts, Immunome Inc (IMNM) has an overall rating of Buy, with a price target of 35.50.
What is the Earnings Per Share (EPS TTM) of Immunome Inc (IMNM)?
The Earnings Per Share (EPS TTM) of Immunome Inc (IMNM) is -2.43.